them that I do not want to spend my valuable time talking about the theoretic advantages of introducing yet another \$1300+ coil to my practice, but instead I want to talk about *value*, which is a ratio of proven quality over cost. We can get proved quality from several vendors; so the question now is, which vendors can give us lower costs?

Partnering with our hospitals, we should be able to push vendors to give us the products that we want at competitive pricing. We need to make it clear to vendors that controlling device expenses is a priority and will be a central theme of our partnership with them in the future. If we do not, I suspect that we will eventually find that hospitals can no longer afford to take care of our patients.

References

1. Hoh BL, Chi YY, Dermott MA, et al. The effect of coiling versus clipping of ruptured and unruptured cerebral aneurysms on length of stay, hospital cost, hospital reimbursement, and surgeon reimbursement at the University of Florida. *Neurosurgery* 2009;64:614–19
2. Girion L, Medina M. Hospitals feel ill effects of recession. *Los Angeles Times*. January 14, 2009. Available at: <http://articles.latimes.com/2009/jan/14/business/fi-hospitals14>. Accessed March 10, 2009
3. Cloft HJ. What is all of the hype about? *AJNR Am J Neuroradiol* 2008;29:1604

H.J. Cloft

Senior Editor

DOI 10.3174/ajnr.A1638

EDITORIAL

Tissue-Specific MR Imaging in Multiple Sclerosis

Conventional MR imaging techniques (cMRI), such as T2-weighted sequences and gadolinium-enhanced T1-weighted sequences, which are highly sensitive for detecting multiple sclerosis (MS) plaques, have become established as the most important paraclinical tool for diagnosing MS, as well as for understanding the natural history of the disease and monitoring the efficacy of experimental treatments. In fact, cMRI metrics have become common primary end points in phase II immunomodulatory drug therapy trials.¹ However, a possible role of cMRI metrics as surrogate end points in phase III trials has been disclaimed because of the poor correlation between cMRI metrics and the clinical disease course, particularly disability progression, which is driven by the neurodegenerative component of the disease.²

Explanations for this clinical-radiologic discrepancy include inappropriate clinical rating, neglect of spinal cord involvement, underestimation of damage to the normal-appearing brain tissue (both white and gray matter), and compensation by cortical adaptation.³ However, one of the major contributors to this paradox is the lack of pathologic specificity of T2-weighted imaging, which provides only a dichotomous type of information, that is, it simply discriminates between MS focal lesions and normal-appearing white matter but not between the type and degree of the underlying pathologic substrates (edema, inflammation, demyelination, remyelination, reactive gliosis, and axonal loss)⁴ that contribute differently to the development of permanent disability.

In the last 15 years, a huge effort has been made by the MR imaging research community to overcome the limited pathologic specificity of cMRI by developing new MR imaging techniques that selectively measure the more destructive aspects of MS pathology and monitor the reparative mechanisms, such as T1 hypointense lesions, quantitative analysis of global and regional brain volume, magnetization transfer MR imaging, diffusion-weighted MR imaging, and proton MR spectroscopy. These techniques appear to be more sensitive biomarkers for measuring the pathologic processes underlying the progression of clinical disability (demyelination and axonal loss).⁵

The first MR imaging–based measure proposed as a specific marker of focal MS lesions with severe tissue destruction was T1 hypointense lesions.⁶ However, these so-called T1 “black holes” may have a different pathologic substrate depending, in part, on the lesion age. Hypointensity is present in $\leq 80\%$ of recently formed lesions and likely represents marked edema, with or without myelin destruction or axonal loss. In most cases, acute (“wet”) black holes become isointense or slightly hypointense within a few months, as inflammatory activity abates, edema resolves, and reparative mechanisms such as remyelination become active, resulting in partial axonal preservation. Less than 40% evolve into persisting or chronic black holes,^{7,8} which correlate pathologically with permanent demyelination and severe axonal loss. Several immunomodulatory drugs (glatiramer acetate, interferon beta, and natalizumab) reduce the progression of acute gadolinium-enhancing lesions into persistent or chronic black holes, supporting a certain neuroprotective effect of these treatments by disrupting the advancement of tissue destruction.^{9–11}

However this MR imaging–based measure has some important drawbacks that limit its use as a true marker of severe irreversible tissue damage. One of the most important limitations is the fact that the definition of what constitutes a black hole is arbitrary, highly dependent on the MR imaging technique used, and based on visual inspection. Therefore, it remains a challenge to accurately discriminate between slightly/moderately and strongly hypointense T1 lesions, which reflect different degrees of remyelination and axonal loss. This pathologic heterogeneity has been demonstrated by postmortem studies¹² and by in vivo MR spectroscopy and magnetization transfer imaging studies, which have shown that tissue damage is extremely variable in individual black holes.^{13,14} Consequently, patients with similar black hole lesion volume may have different degrees of disability depending on the nature of the histopathologic substrate.

For this reason, new ways of measuring black holes have been recently developed, such as the T1 hypointensity ratio¹⁵ and the one proposed in this issue of *American Journal of Neuroradiology* by Riva et al.¹⁶ These authors assessed the ability of a new MR imaging technique, which they call “tissue-specific imaging” to selectively identify black holes with the longest T1 values, which likely reflect lesions with severe demyelination and axonal loss. The results of this study are promising and provide data indicating that this technique could be a sensitive method for detecting and quantifying hypointense T1 lesions with more advanced tissue destruction. Nevertheless, additional studies are required before new MR imaging–based measures can be considered markers of disease severity and progression in MS or surrogate markers of remyelination and

neuronal protection in clinical trials. These additional studies should demonstrate their reproducibility, sensitivity to disease evolution and treatment changes, and their value in reflecting and predicting the accumulation of irreversible disability.¹⁷

All these necessary efforts are especially important nowadays, when there is a growing interest in developing neuroprotective agents in MS, which consequently demands new imaging strategies for achieving and monitoring myelin repair and axonal loss.¹⁸

References

1. Sormani MP, Bonzano L, Roccatagliata L, et al. **Magnetic resonance imaging as a potential surrogate for relapse in multiple sclerosis: a meta-analytic approach.** *Ann Neurol* 2009;65:270–77
2. Goodin DS. **Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?** *Ann Neurol* 2006;59:597–05
3. Barkhof F. **The clinico-radiological paradox in multiple sclerosis revisited.** *Curr Opin Neurol* 2002;15:239–45
4. Barkhof F, Bruck W, De Groot CJ, et al. **Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.** *Arch Neurol* 2003;60:1073–81
5. Arnold DL. **Evidence for neuroprotection and remyelination using imaging techniques.** *Neurology* 2007;68(suppl 3):S83–S90
6. Van Walderveen MA, Barkhoff F, Hommes OR, et al. **Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images.** *Neurology* 1995;45:1684–90
7. Bagnato F, Jeffries N, Richert ND, et al. **Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.** *Brain*. 2003;126(Pt 8):1782–89
8. Zivadinov R. **Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?** *Neurology* 2007;68(suppl 3):S72–S82
9. Filippi M, Rovaris M, Rocca MA, et al, and the European/Canadian Glatiramer Acetate Study Group. **Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes.”** *Neurology* 2001;57:731–33
10. Dalton CM, Miskiel KA, Barker GJ, et al. **Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.** *J Neurol* 2004;251:407–13
11. Bagnato F, Gupta S, Richert ND, et al. **Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.** *Arch Neurol* 2005;62:1684–88
12. Van Walderveen MA, Kamphorst W, Scheltens P, et al. **Histopathologic correlates of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.** *Neurology* 1998;50:1282–88
13. Li BS, Moriarty DM, Regal J, et al. **In vivo 3D 1H MRS of T1-hypointense lesions in relapsing-remitting multiple sclerosis.** In: *Proceedings of the International Society for Magnetic Resonance in Medicine*, Glasgow, Scotland, UK, April 21–27, 2001
14. Barkhof F, Karas GB, van Walderveen MA. **T1 hypointensities and axonal loss.** *Neuroimaging Clin N Am* 2000;10:739–52
15. Fritz D, Dwyer MG, Quadros C, et al. **T1 intensity differences to normal appearing white matter in hypointense lesions on MRI are related to clinical status in multiple sclerosis.** *J Neurol* 2006;253:104–26
16. Riva M, Ikonomidou VN, Ostuni JJ, et al. **Tissue-specific imaging as a robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage.** *AJNR Am J Neuroradiol* 2009;30:1394–401
17. Miller DH. **Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.** *NeuroRx* 2004;1:284–94
18. Rice C, Scolding N. **Strategies for achieving and monitoring myelin repair.** *J Neurol* 2007;254:275–83

À. Rovira

Magnetic Resonance Unit (I.D.I.)

Department of Radiology

Hospital Universitari Vall d'Hebron

Barcelona, Spain

DOI 10.3174/ajnr.A1777